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Abstract
Pregnant women with type 1 diabetes (T1D) experience increased glycemic variability as
a result of changing insulin sensitivity and resistance throughout gestation. Therefore, strategies
that help pregnant women with T1D manage their glycemic control are of great interest. We
examined whether remote monitoring of Continuous Glucose Monitor (CGM) data by friends
and family affects glycemic variability during pregnancy compared to CGM use alone in a pilot
non-randomized trial (n = 28). During preconception or the first trimester, women with T1D
were placed in one of two groups based on device compatibility: (1) CGM Alone (n = 13):
women without iPhone, iPad or iPod Touch; or (2) CGM Share (n = 15): women with iPhone,
iPad, or iPod Touch and followers with devices compatible for data viewing. Linear mixed
models and t-tests we used to compare indices of glycemic control and glycemic variability over
time between groups and during each trimester. Mean sensor glucose was lower in the CGM
Share group than the CGM Alone group (p = 0.003). Estimated hemoglobin A1c from CGM data
decreased in both groups as pregnancy progressed and was significantly lower over time in
women using CGM Share compared to CGM Alone (p = 0.028). Glucose management index
was also lower among women in the CGM Share group (p = 0.041, Table 2). Average number
of excursions above 200 mg/dL was higher in the CGM Alone group (p = 0.021). In this small
pilot study, use of CGM with remote monitoring was associated with a lower risk of
hyperglycemia, lower standard deviation, and lower area under the curve. However, other
measures of glycemic variability including mean amplitude of glucose excursions, and
coefficient of variation, were similar between groups. A larger, randomized study is warranted to
confirm if CGM Share use helps pregnant women with T1D achieve tighter glucose control
across multiple clinical measures.
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Glycemic Variability and Indices of Glycemic Control among Pregnant Women with Type
1 Diabetes (T1D) Based on Use of Continuous Glucose Monitoring Share Technology
MANUSCRIPT:
Introduction
Pregnancies complicated by type 1 diabetes (T1D) are associated with a high rate of
maternal and neonatal complications, with an estimated 50% of newborns experiencing
complications associated with maternal hyperglycemia1. While significant advances have been
made regarding treatment options to improve glycemic control in pregnancies among women
with T1D, there have been minimal improvements in neonatal morbidity over the past several
decades2.
Tightly regulating blood glucose levels and decreasing hemoglobin A1c (HbA1c) to the
normal or near-normal range, without inducing significant hypoglycemia, before and throughout
gestation is associated with a reduced risk of adverse health outcomes3,4. HbA1c has long been
considered the gold standard measure of glycemic control. Yet, a growing body of evidence lead
to a consensus statement by multiple leading scientific organizations suggesting that HbA1c
should be supplemented by data from continuous glucose monitoring (CGM). The consensus
statement includes a pregnancy-specific time in range (63-140 mg/dL)5. An emerging body of
evidence suggests that measures of CGM-derived glycemic control (like time in range) and of
glycemic variability (GV), may provide a more comprehensive understanding of glycemic
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fluctuations within and between days compared to the HbA1c alone6. Several studies have also
suggested that GV may be a predictor independent of HbA1c of micro- and macrovascular
complications in patients with T1D7. Though these data were derived from non-pregnant
populations, the associations between GV and complications may be particularly true during
pregnancy, as evidenced by the CONCEPTT trial8. The CONCEPTT trial was a large,
international multi-center study wherein women with T1D either in preconception or in
pregnancy were randomized to CGM therapy or self-monitoring of blood glucose levels for the
remainder of their pregnancies8. The use of CGM was associated with significant reductions in
rates of multiple adverse neonatal outcomes (large-for-gestational age infants, neonatal
hypoglycemia requiring intravenous dextrose, neonatal intensive care unit stays >24 hours), but
only a modest reduction in HbA1c (6.53% control group vs. 6.35% CGM group, p=0.021 for
difference between groups of the mean difference of HbA1c over pregnancy). The significant
and clinically meaningful reduced rates of adverse neonatal outcomes despite similar HbA1c
levels between groups may be due to factors beyond HbA1c, specifically improved glucose
control (time in range) and reductions in GV measures (e.g. standard deviation (SD), mean
amplitude of glucose excursions (MAGE), and rate of change) which were significantly different
between the arms9.
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A limited number of trials have assessed whether diabetes technology interventions
minimize glycemic fluctuations and/or reduce adverse outcomes for pregnant women and their
neonates. Among diabetes technology studied in pregnancy, data on remote monitoring has been
particularly scarce. Remote monitoring is technology in which followers of patients can view
glucose trends and receive glucose alerts, with providers and/or patient supporters (e.g. family
members) being followers. In the several studies assessing the role of remote monitoring of
pregnant women by providers, there have been conflicting results with some showing lowered
mean blood glucose and J-indices10 and others showing no significant differences in HbA1c11,12.
However, none of these studies have assessed the impact of remote monitoring by family/friends,
as opposed to providers, on glycemic control in pregnant women.
To understand more about if Share Technology could be beneficial in pregnancies
complicated by T1D, we conducted a pilot intervention study among pregnant women with T1D
comparing CGM use by itself (CGM Alone) to CGM use with remote monitoring by family and
friends (CGM Share). Previously, we reported on the effect of CGM Share on HbA1c, median
sensor glucose levels, maternal and neonatal outcomes, and fear of hypoglycemia 13 Presently,
we evaluate the effect of CGM with and without remote monitoring on other indices of glycemic
control and GV.
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Materials and Methods:
Study Design and Stratification
This single-center, open-label, non-randomized, investigator-initiated pilot study
prospectively enrolled two cohorts of patients: (1) women with T1D who were within the first
trimester of gestation or who were seen for preconception care, and (2) followers (family and
friends) of pregnant women with T1D within the first trimester. We previously reported the full
study design and methods14, but briefly, pregnant women enrolled in the study were
prospectively stratified to one of two groups based on device compatibility and willingness to
wear a CGM: (1) CGM use with Share (CGM Share): women with iPhone, iPad, or and
followers with devices compatible for data viewing or (2) CGM use alone (CGM alone): women
without iPhone, iPad, or iPod Touch. At the time of study enrollment, CGM Share was not
available on Android devices.

Study Procedures
Participants were given the Dexcom G4 system for the duration of their pregnancy, or the
Dexcom G5 sensors if they were using this system prior to study enrollment. Pregnant
participants were trained on the use of the Dexcom G4/G5 Platinum CGM system with ShareTM
(CGM Share) or without Share (CGM Alone) depending on their group assignments. Share is a
Bluetooth low energy secure wireless communication system. Share allows remote viewing of
sensor glucose levels, trends, and data between the person with diabetes wearing the CGM and
her designated family members/friends, and provides alerts (alarms) for prespecified low and
high CGM values.
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Pregnant women came to the Barbara Davis Center Pregnancy & Women’s Health Clinic
at least once a month for routine peri-partum care and study visits. Participants were seen for a
final post-partum study visit between 4 weeks and 3 months after delivery. Glucose meters,
insulin pumps, and CGMs were downloaded throughout the study, and point-of-care HbA1c
levels were collected at each study visit. As acetaminophen use may affect CGM device
performance15, women were instructed to document each use both as an event marker in the
CGM system and on paper.

Statistical Analysis
Participant data were excluded from analysis in the case of miscarriages without reenrollment in the study from a subsequent pregnancy, participant drop-outs, and investigator
withdrawal of participants. CGM data within 12 hours of acetaminophen use were also excluded.
Demographic and clinical characteristics of the groups were compared using Wilcoxon MannWhiney U-test for continuous variables or Fisher exact tests for categorical variables. Linear
mixed models were used to compare indices of GV and glycemic control over time. Trimester of
pregnancy was treated as a categorical variable to assess nonlinear trajectories over time. For
each GV measure and indices of glycemic control, the interaction between group and time was
evaluated to assess whether trajectories varied by group. Non-significant interactions were
removed. The mean values of each indices of GV and control across trimesters were compared
using t-tests. Multiple regression analysis was conducted to assess the predictive ability of
baseline characteristics on mean measures of GV during the second trimester that were found be
statistically significantly different between CGM Share and CGM Alone. Study data were
collected and managed using REDCap electronic data capture tools hosted at the University of
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Colorado Denver. All statistical analyses were conducted using SAS Version 9.4 and statistical
significance was set at p = 0.05.

Results:
Forty women were prospectively enrolled during preconception (n=15) and the first
trimester of gestation (n =25). Eight women in the preconception group became pregnant within
the study period (53%). Two women had miscarriages and became pregnant again during the
study period in the preconception group, thus they were re-enrolled. There were 5 miscarriages,
1 woman dropped out, and 1 woman was withdrawn, leaving a total of 28 out of 35 pregnancies
for analyses. There were 13 women assigned to CGM Alone and 15 assigned to CGM Share.
There were no significant differences in median age, diabetes duration, body mass index,
basal insulin, and bolus insulin between pregnant women in the CGM Alone group and CGM
Share group at the preconception baseline (Table 1). Significantly more women in the CGM
Alone group reported a history of past cigarette use (67% CGM alone, 20% CGM Share, p =
0.034). There were borderline significant differences in method of insulin delivery, with more
women in the CGM Alone group using multiple daily injection (MDI) therapy at baseline (54%
CGM Alone, 13% CGM Share, p = 0.055) when compared to women in the CGM Share group.
Additionally, women in the CGM Alone group had non-significant, but clinically meaningful,
higher median baseline HbA1c (8.1% CGM Alone, 7.1% CGM Share, p = 0.112) when
compared to women using CGM Share (Table 1).
During follow-up, mean sensor glucose was significantly lower in CGM Share users than
CGM Alone users in each trimester (p = 0.033) (Table 2). Estimated HbA1c from CGM data
decreased in both groups as pregnancy progressed and was significantly lower over time in
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women using CGM Share compared to CGM Alone (p = 0.028). Glucose management index
(GMI) was also lower among women in the CGM Alone group (p = 0.041). Time spent under
63 mg/dL and over 140 mg/dL were similar between the two groups. Average number of
excursions over 200 mg/dL was significantly lower in CGM Share users (p=0.021). Although
statistically insignificant, there was a trend in which those in the CGM share group, spent more
time in the pregnancy-specific time in range of 63 to 140 mg/dL (0.060).
Those in the CGM Alone group had a significantly higher High Blood Glucose Index
(HBGI) and mean area under the curve (AUC) than those in the CGM Share group in each
trimester (p = 0.012 and p = 0.261, respectively) (Table 3). Those in the CGM Alone group also
had a lower standard deviation compared to those in the CGM Share group (p = 0.046). Other
measures of GV including the coefficient of variation, mean amplitude of glycemic excursions
(MAGE), and low blood glucose index (LBGI) were similar between the two groups.
Finally, we also evaluated baseline characteristics as potential predictors of mean HBGI,
AUC, and SD during the second trimester, but there were no statistically significant associations
in our multivariate regression model (data not shown).

Discussion:
In this pilot study of 28 pregnancies complicated by T1D, we found that use of CGM with
remote monitoring was associated with a lower risk of hyperglycemia (HBGI), lower standard
deviation, and lower area under the curve (AUC). However, other measures of GV (MAGE and
coefficient of variation) were similar between groups. As previously reported, while HbA1c
decreased in both groups throughout the pregnancy, HbA1c over time was significantly lower
among women using CGM Share compared to CGM Alone compared to preconception HbA1c
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levels 14. Mean sensor glucose was also lower among women in CGM Share compared to CGM
alone.
The effect of remote monitoring by friends and family on GV and other glycemic control
parameters in pregnant women has not previously been assessed, to our knowledge. However,
there are studies using interventions with remote monitoring by providers and studies with
family or friends as followers conducted in non-pregnant diabetic populations. One study
assessed the effect of remote monitoring by providers compared to standard of care weekly
clinical examinations. Providers reviewed data collected and uploaded by pregnant patients with
T1D every day and communicated modifications by phone to participants. Among those in the
intervention group, there was a significant improvement in GV (J-index) when compared to
those in the control group10. Another study assessed the effect of real-time CGM monitoring by
parents and daytime caregivers in school-aged children, but did not assess the effect on GV16.
They found that all parents and caregivers reported improved psychosocial measures such as
decreased overall worry/stress. Remote monitoring by providers has also been studied in a
diabetes camp setting, with one study reporting a significant reduction in prolonged nocturnal
hypoglycemia, such that campers without remote monitoring had a median duration of
hypoglycemic events <70 mg/dL of 35 minutes compared to those with remote monitoring
having a median duration of 30 minutes (p = 0.078)17.
In our study of pregnant women with T1D followed by a non-provider population, we found
a significant reduction in HBGI, AUC, and SD. We also found numerical reductions in other
indices of GV such as MAGE and LBGI, favoring CGM Share, though they did not meet
statistical significance. A larger randomized trial could more definitely assess if indices of
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glycemic control and GV would differ with an intervention utilizing remote monitoring by
friends and/or family.
This finding of reduced HBGI, AUC, and standard deviation in this high-risk population
should be interpreted with caution, as this was a pilot study, but nonetheless, may have clinical
implications. First, the Hyperglycemia and Adverse Outcomes Study (HAPO) measured glucose
values before, 1 hour, and 2 hours after a glucose load (oral glucose tolerance tests) in pregnant
women and analyzed the data based on septiles of glucose control. They found that increases in
all these values were independently associated with birth weight >90th percentile, cesarean
delivery, and neonatal hypoglycemia. These findings were based on a single oral glucose
tolerance test performed between 24 and 32 weeks gestation18. The CONCEPTT study found that
in pregnant women with T1D randomized to CGM or self-monitoring of blood glucose
throughout gestation, the mean HbA1c levels were similar between groups (and similar to the
mean HbA1C levels in our cohort as well). Yet, CGM time in range and time spent >140 mg/dL
were significantly lower in the CGM group. These differences may be enough to reduce rates of
adverse neonatal outcomes. This provides additional evidence that in pregnancy, glycemic
excursions are clinically meaningful and impactful9. Second, outside of pregnancy reduced
glycemic fluctuations are associated with a higher quality of life. If such a relationship also exists
in pregnancy, this is particularly important as pregnancies complicated by T1D are associated
with lower psychological well-being and quality of life18–21.
Our study has several strengths. To our knowledge, this was the first study that has analyzed
the role of remote monitoring by family and friends of pregnant women on GV and other
glycemic parameters. All participants used CGM devices manufactured by the same company
and the adherence to CGM use was high. However, our study has some limitations that should be

13

noted. First, our power to detect differences across all measures of GV and glycemic control may
have been limited due to this being a small pilot study. Additionally, this was a non-randomized
trial. At the time of study enrollment, CGM Share was not available on Android devices and the
option of providing all study participants with CGM Share compatible devices was cost
prohibitive. This may have introduced confounding in that the CGM Share arm may have
underlying differences for which we have not accounted and which may be associated with a
difference in socioeconomic status. There were underlying differences between the two groups,
most notably the method of insulin delivery at baseline and maternal cigarette use.

Conclusions:
In this non-randomized pilot study, remote monitoring of sensor glucose trends and realtime alerts by family/friends (CGM Share) was associated with a lower risk of hyperglycemia in
pregnancies complicated by T1D. Remote monitoring by a non-provider population may have
therapeutic potential to assist pregnant women to optimize glucose control during gestation.
Larger randomized trials are needed to see whether there is a reduction in other GV indices and
if the findings of this pilot can be replicated.
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Table 1. Characteristics at First Pregnancy Visit by CGM Share Status
Characteristic
CGM Alone (n =13)
CGM Share (n =15)
Age (years) ab
24.4 (21.2, 30.3)
28.9 (26.7, 31.0)
Diabetes durations (years) a
13.2 (7.0, 19.0)
18.0 (10.0, 21.0)
Body mass index (kg/m2)
25.8 (24.6, 28.5)
24.7 (24.2, 31.4)
Past cigarette use, n (%) b
8 (67)
3 (20)
Method of insulin delivery
Baseline
Follow-up
Baseline
Follow-up
Multiple daily injections) bc
7 (54)
4 (31)
2 (13)
0 (0)
Insulin pump therapy
6 (46)
9 (69)
13 (87)
15 (100)
Basal insulin (units) a
32.5 (20.0, 54.0)
23.1 (18.6, 30.0)
Bolus insulin a
24.1 (15.5, 31.9)
19.7 (14.3, 28.3)
Preconception HbA1c (%) a
8.1 (7.2, 9.0)
7.1 (6.3, 8.4)
Abbreviations: CGM, continuous glucose monitor
a Median (25th percentile, 75th percentile)
b P-value < 0.05 at baseline
c Three women on CGM Alone and two on CGM Share changed MDI to insulin pump therapy
during the pregnancy ( p = 0.07)

17

Table 2: Indices of Glycemic Control by CGM Share Status among Pregnant Women with T1D
CGM Alone
CGM Share
Trimester Glycemic Control Index
Mean glucose (mg/dL)*
131 (120.9, 148.1)
Estimated HbA1c (%)
6.2 (5.9, 6.8)
GMI
6.5 (4.5, 8.9)
1
Time spent below 63 mg/dL (%)
7.3 (4.5, 8.9)
Time spent 63-140 mg/dL (%)
52.9 (46.6,74.1)
Time spent above 140 mg/dL (%)
35.6 (21.7,49.0)
Average excursions > 140 mg/dL
2.8 (2.3, 3.1)
Average excursions > 200 mg/dL*
1.30 (0.8, 1.9)
Mean glucose (mg/dL)c
140 (123.9, 154.8)
Estimated HbA1c (%)
6.5 (5.9, 7.0)
GMI
6.7 (6.30, 7.00)
2
Time spent below 63 mg/dL (%)
4.84 (3.62, 7.35)
Time spent 63-140 mg/dL (%)
50.7 (44.1, 58.1)
Time spent above 140 mg/dL (%)
38.2 (21.7, 49.0)
Average excursions > 140 mg/dL
46.1 (30.4,51.1)
Average excursions > 200 mg/dL*
12.9 (5.9, 21.0)
Mean glucose (mg/dL)c
141 (128.2, 151.4)
Estimated HbA1c (%)
6.5 (6.1, 6.9)
GMI
6.7 (6.4, 6.9)
3
Time spent below 63 mg/dL (%)
4.1 (3.4, 4.4)
Time spent 63-140 mg/dL (%)
53.4 (42.8,59.6)
Time spent above 140 mg/dL (%)
44.9 (35.4,52.8)
Average excursions > 140 mg/dL
2.7 (2.5, 3.0)
Average excursions > 200 mg/dLc
1.3 (0.9, 1.7)
Abbreviations: GMI, glucose management index.
* P-value < 0.05 for group difference.
Descriptive statistics are median (25th percentile, 75th percentile)

128 (115.1, 136.4)
6.1 (5.6, 6.4)
6.4 (6.1, 6.6)
7.1 (3.4, 8.2)
60.0 (54.6,69.0)
34.0 (24.3,41.0)
2.7 (2.4, 3.2)
1.03 (0.3, 1.5)
131 (111.3, 140.8)
6.0 (5.5, 7.1)
6.40 (6.00, 6.70)
5.20 (3.91, 8.12)
56.8 (48.8, 69.1)
35.1 (24.3, 41.0)
37.2 (21.9,43.1)
9.1 (2.4,15.5)
131 (112.1, 142.5)

6.0 (5.5, 6.5)
6.40 (6.0, 6.7)
4.2 (3.3, 5.9)
62.4 (50.0,70.5)
34.4 (23.2,46.8)
2.5 (2.2, 2.9)
0.70 (0.3, 1.2)
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Table 3: Indices of Glycemic Variability by CGM Share Status among Pregnant Women with
T1D
Trimester Glycemic Variability Index
CGM Alone
CGM Share
Coefficient of Variation
0.39 (0.33, 0.44)
0.38 (0.36, 0.39)
MAGE mg/dL (%)
100.4 (63.8, 112.6)
75.1 (73.2, 86.7)
LBGI (%)
4.9 (4.5, 6.4)
4.9 (3.9, 5.4)
1
HBGI (%) *
7.2 (3.1, 8.4)
5.3 (3.9, 5.8)
1.9 e 105 (1.7 e 105, 2.2e 105) 1.8e105 (1.7 e 105, 1.9 e 105)
Average AUC per day *
Standard deviation *
55.7 (36.1, 60.7)
45.9 (41.3, 49.2)
Coefficient of Variation
0.39 (0.35, 0.44)
0.35 (0.35, 0.38)
MAGE mg/dL (%)
91.1 (76.3, 103.3)
81.7 (67.2, 92.1)
LBGI (%)
4.9 (4.1, 5.7)
4.8 (4.3, 4.9)
2
HBGI (%) *
6.8 (5.6, 9.9)
4.8 (3.3, 6.9)
2.0 e 105 (1.8 e 105, 2.2e 105) 1.8 e 105 (1.6 e 105, 2.0 e 105)
Average AUC per day *
Standard deviation *
53.0 (47.6, 64.5)
46.5 (39.0, 61.7)
Coefficient of Variation
0.37 (0.35, 0.41)
0.33 (0.31, 0.38)
MAGE mg/dL (%)
92.1 (76.3, 108.9)
75.6 (63.6, 81.1)
LBGI (%)
4.3 (3.7, 6.3)
4.1 (3.8, 5.3)
3
HBGI (%) *
6.3 (5.2, 9.0)
4.4 (3.1, 5.8)
2.0 e 105 (1.9 e 105, 2.2e 105) 1.8 e 105 (1.6 e 105, 2.0e 105)
Average AUC per day *
Standard deviation *
50.1 (45.0, 65.1)
41.9 (38.1,49.8)
Abbreviations: MAGE, mean amplitude of glycemic excursion, LBGI, low blood glucose index, HBGI,
high blood glucose index, AUC, area under the curve.
*P-value < 0.05 for group difference
Descriptive statistics are median (25th percentile, 75th percentile)
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